mekinist
novartis europharm limited - trametinib - melanomul - agenți antineoplazici - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 și 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-cancer pulmonar cu celule mici (nsclc)trametinib în combinație cu dabrafenib este indicat pentru tratamentul pacienților adulți cu avansate non-cancer pulmonar cu celule mici, cu o mutație braf v600.
tafinlar
novartis europharm limited - dabrafenib mesilate - melanomul - agenți antineoplazici - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 și 5. tratamentul adjuvant al melanomadabrafenib în combinație cu trametinib este indicat pentru tratamentul adjuvant al pacienților adulți cu etapa a iii-a melanom cu mutație braf v600, în urma rezecției complete. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
mekinist 0,5 mg
glaxo wellcome, s.a. - spania - trametinibum - compr. film. - 0,5mg - inhibitori de protein-kinaza
mekinist 2 mg
glaxo wellcome, s.a. - spania - trametinibum - compr. film. - 2mg - inhibitori de protein-kinaza
spexotras 0,05 mg/ml
sandoz s.r.l. - romania - trametinibum - pulb. pt. sol. orala - 0,05mg/ml - inhibitori de protein-kinaza inhibitori ai proteinei kinazei activate de mitogen (mek)
gavreto
roche registration gmbh - pralsetinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
gavreto 100 mg
roche pharma ag - germania - pralsetinibum - caps. - 100mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
ketilept comprimate filmate 300 mg
egis pharmaceuticals plc - quetiapinum - comprimate filmate - 300 mg
ketilept comprimate filmate 100 mg
egis pharmaceuticals plc - quetiapinum - comprimate filmate - 100 mg
ketilept comprimate filmate 150 mg
egis pharmaceuticals plc - quetiapinum - comprimate filmate - 150 mg